Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Neurogastroenterol Motil. 2018 Jul;30(7):e13307. doi: 10.1111/nmo.13307. Epub 2018 Feb 2.
Acupuncture is used to treat chronic functional constipation (CFC) in China, despite limited evidence. We aim to assess the effectiveness and safety of acupuncture in managing CFC.
A multicenter randomized controlled trial was performed involving 684 patients with CFC; the patients were randomly allocated to receive He acupuncture (n = 172), Shu-mu acupuncture (n = 171), He-shu-mu acupuncture (n = 171), or oral administration of mosapride (n = 170). Sixteen sessions of acupuncture were given in the treatment duration of 4 weeks. The primary outcome was the change in spontaneous bowel movements (SBMs) at week 4 (at the end of treatment) compared to baseline. The secondary outcomes included stool consistency (Bristol scale), the degree of straining during defecation, and adverse events.
The SBMs increased in all the four groups at week 4, and the magnitude of increase was equivalent in the four groups (He acupuncture, 2.7 [95% CI, 2.3-3.1]; Shu-mu acupuncture, 2.7 [95% CI, 2.3-3.0]; He-shu-mu acupuncture, 2.2 [95% CI, 1.9-2.5]; and mosapride, 2.4 [95% CI, 2.0-2.9]; P = .226). However, the change in SBMs at week 8 was significantly smaller in mosapride group (1.4 [95% CI, 1.0-1.8]) than the three acupuncture groups (2.4 [95% CI, 2.1-2.7], 2.3 [95% CI, 1.9-2.7], 2.1 [95% CI, 1.7-2.5] in He, Shu-mu, and He-shu-mu group, respectively, P = .005).
CONCLUSIONS & INTERFERENCES: The three acupuncture treatments were as effective as mosapride in improving stool frequency and stool consistency in CFC, but the magnitude of the treatment effect is unknown due to the lack of sham acupuncture control.
尽管证据有限,中国仍将针灸用于治疗慢性功能性便秘(CFC)。我们旨在评估针灸治疗 CFC 的有效性和安全性。
一项多中心随机对照试验纳入了 684 例 CFC 患者,患者被随机分配接受 He 针刺(n=172)、Shu-mu 针刺(n=171)、He-shu-mu 针刺(n=171)或口服莫沙必利(n=170)治疗。在 4 周的治疗期间,给予 16 次针刺治疗。主要结局是与基线相比,第 4 周(治疗结束时)的自发排便次数(SBMs)变化。次要结局包括粪便稠度(Bristol 量表)、排便时用力程度和不良事件。
在第 4 周时,所有四组的 SBMs 均增加,四组增加幅度相同(He 针刺,2.7 [95%CI,2.3-3.1];Shu-mu 针刺,2.7 [95%CI,2.3-3.0];He-shu-mu 针刺,2.2 [95%CI,1.9-2.5];莫沙必利,2.4 [95%CI,2.0-2.9];P=0.226)。然而,莫沙必利组在第 8 周时 SBMs 的变化明显小于三组针刺组(1.4 [95%CI,1.0-1.8]),分别为 He、Shu-mu 和 He-shu-mu 组的 2.4 [95%CI,2.1-2.7]、2.3 [95%CI,1.9-2.7]和 2.1 [95%CI,1.7-2.5],P=0.005)。
三种针刺治疗与莫沙必利治疗 CFC 一样有效,可改善粪便频率和粪便稠度,但由于缺乏假针刺对照,治疗效果的幅度尚不清楚。